Trial · NCT05050955
AlloSure Lung Assessment and Metagenomics Outcomes Study
NCT05050955, Active not recruiting, CareDx
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. AlloSure Lung Assessment and Metagenomics Outcomes Study. Trials, record NCT05050955. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05050955
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- AlloSure Lung Assessment and Metagenomics Outcomes Study
- NCT number
- NCT05050955
- Status
- Active not recruiting
- Enrollment
- 550 participants, actual
- Lead sponsor
- CareDx
- Conditions
- Lung Transplant Infection, Lung Transplant; Complications, Lung Transplant Failure and Rejection
- First posted
- 2021-09-21
- Last updated
- 2026-06-25
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | ALAD | 1 year post-transplant | Diagnostic performance characteristics (sensitivity, specificity, PPV, NPV) of AlloSure Lung to detect acute lung allograft dysfunction (ALAD). |
| Secondary | Chronic lung allograft dysfunction | 3 years post-transplant | Clinical diagnostic performance characteristics (sensitivity, specificity, PPV and NPV) of AlloSure Lung to detect chronic lung allograft dysfunction. |
| Secondary | Acute cellular rejection | 3 years post-transplant | Clinical diagnostic performance characteristics (sensitivity, specificity, PPV and NPV) of AlloSure Lung to detect acute cellular rejection (ACR). |
| Secondary | Antibody mediated rejection | 3 years post-transplant | Clinical diagnostic performance characteristics (sensitivity, specificity, PPV and NPV) of AlloSure Lung to detect antibody mediated rejection (AMR). |
| Secondary | Acute infection | 3 years post-transplant | Clinical diagnostic performance characteristics (sensitivity, specificity, PPV and NPV) of AlloSure Lung to detect acute infection. |
| Secondary | Subject Variability | 3 years post-transplant | Define within-subject and between-subject variability of AlloSure Lung in clinically stable patients in order to establish reference change value RCV. |
| Secondary | ALAD vs. Stability | 3 years post-transplant | Evaluate the diagnostic performance characteristics of utilizing RCV to distinguish ALAD vs. Stability |
| Secondary | Biopsy-proven rejections | 3 years post-transplant | The proportion of biopsy-proven rejections with elevated AlloSure Lung versus those without elevated AlloSure-Lung. |
| Secondary | AlloSure Lung Results | 3 years post-transplant | The proportion of AlloSure Lung results obtained as surveillance or for-cause, that the physicians felt influenced their decisions around management of patients. |
| Secondary | ALAD Free survival | 3 years post-transplant | ALAD free survival in lung transplant recipients who received AlloSure Lung as part of post-transplant surveillance. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05050955
GET https://conductscience.org/api/trials/v1/NCT05050955/registered